Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

Outlook Therapeutics, Inc.

U.S. stocks finished a strong week with another rally on Friday after a surprisingly weak jobs report pushed investors to rethink the path for inte...

The Week That Was, The Week Ahead: Macro and Markets, August 9

Insiders have been trading these 5 stocks: (($DRI)), (($OTLK)), (($BYD)), (($GRMN)) and (($SMG)). Here is a breakdown of their recent trades and th...

Darden, Outlook, Boyd, Garmin, Scotts: Insider Trade Shock

Analysts are intrested in these 5 stocks: ( ($OTLK) ), ( ($HBAN) ), ( ($CORT) ), ( ($CAPR) ) and ( ($GOSS) ). Here is a breakdown of their recent


OTLK, HBAN, CORT, CAPR, GOSS Trending With Analysts

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Outlook Therapeutics (OTLK) and Gossamer Bio (GOSS). Outlook Ther...

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Gossamer Bio (GOSS)

The latest announcement is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced that the U.S. FDA approved i...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OTLK	$1.02	+4.88%	4.56M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OTLK	$1.02	+4.9%	4.56M
3
4
5
6

OTLK

OTLK

Get Outlook Therapeutics, Inc. Data in Excel

Get Outlook Therapeutics, Inc. Data in Excel